Graphic Online
BY: Emmanuel Adu-Gyamerah
30.5k
Shares
705
The African Cashew Alliance (ACA) has called on African governments to provide an enabling policy environment conducive for business to help position African cashew producers among the leaders in cashew production in the world.
This, ACA believes, is critical to help African countries involved in the cashew industry, fully take advantage of the booming market for cashew in Europe and the USA.
The Managing Director of ACA, Mr Ernest Mintah, while acknowledging the development in Ghana’s cashew sector with the inauguration of the Tree Crop Development Authority (TCDA), said it was not enough as an unwavering support was needed to make it become operational and to be able to fulfil its obligations.
Alcon Inc. Swiss: Alcon Reports First Quarter 2021 Results
Strong commercial execution drives the global launch of new product innovations
Substantially completes separation process
Full year guidance: sales of $7.8 to $8.0 billion and core diluted EPS of $1.85 to $1.95
Regulatory News:
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2021. For the first quarter of 2021, worldwide sales were $1.9 billion, an increase of 5% on a reported basis and 2% on a constant currency basis
(2), as compared to the same quarter of the previous year. First quarter 2021 diluted earnings per share were $0.17 and core diluted earnings per share were $0.49.
Alcon Inc. Swiss: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Builds on company s ophthalmic pharmaceutical manufacturing expertise
Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to
Simbrinza
The acquisition of
Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption.
Alcon Inc. Investors: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Builds on company s ophthalmic pharmaceutical manufacturing expertise
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to
Simbrinza
The acquisition of
Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption.